Ines Zollner-Schwetz1, Kathrin A T Herzog2,3, Gebhard Feierl4, Eva Leitner4, Georg Schneditz2, Hanna Sprenger2, Jürgen Prattes5, Wolfgang Petritsch3, Heimo Wenzl3, Patrizia Kump3, Gregor Gorkiewicz6, Ellen Zechner2, Christoph Högenauer3. 1. Section of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria. ines.schwetz@medunigraz.at. 2. Institute of Molecular Biosciences, University of Graz, Graz, Austria. 3. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria. 4. Institute of Hygiene, Microbiology and Environmental Medicine, Medical University of Graz, Graz, Austria. 5. Section of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria. 6. Institute of Pathology, Medical University of Graz, Graz, Austria.
Abstract
BACKGROUND: Alterations in the intestinal microbiota are thought to be involved in the pathogenesis of inflammatory bowel diseases (IBD). Klebsiella oxytoca is an intestinal pathobiont that can produce a cytotoxin (tillivaline). AIM: We aimed to elucidate the pathogenetic relevance of toxin-producing K. oxytoca in patients with IBD flares and investigated the clonal relationship of K. oxytoca isolates from IBD patients using multilocus sequence typing (MLST). METHODS: Fecal samples of 235 adult IBD patients were collected from January 2008 to May 2009 and were tested for K. oxytoca, C. difficile toxin, and other pathogens by standard microbiological methods. Clinical data and disease activity scores were collected. K. oxytoca isolates were tested for toxin production using cell culture assays. A total of 45 K. oxytoca isolates from IBD patients, healthy, asymptomatic carriers and from patients with antibiotic-associated hemorrhagic colitis in part from our strain collection were tested for their clonal relationship using MLST. RESULTS: The prevalence of K. oxytoca in IBD overall was 4.7%. Eleven K. oxytoca isolates were detected. Two of 11 isolates were tested positive for toxin production. There was no significant difference in the distribution of K. oxytoca isolates between the groups (active vs. remission in UC and CD). MLST yielded 33 sequence types. K. oxytoca isolates from IBD did not cluster separately from isolates from asymptomatic carriers. CONCLUSIONS: Our data demonstrate that toxin (tilivalline)-producing K. oxytoca is not associated with IBD flares.
BACKGROUND: Alterations in the intestinal microbiota are thought to be involved in the pathogenesis of inflammatory bowel diseases (IBD). Klebsiella oxytoca is an intestinal pathobiont that can produce a cytotoxin (tillivaline). AIM: We aimed to elucidate the pathogenetic relevance of toxin-producing K. oxytoca in patients with IBD flares and investigated the clonal relationship of K. oxytoca isolates from IBD patients using multilocus sequence typing (MLST). METHODS: Fecal samples of 235 adult IBD patients were collected from January 2008 to May 2009 and were tested for K. oxytoca, C. difficiletoxin, and other pathogens by standard microbiological methods. Clinical data and disease activity scores were collected. K. oxytoca isolates were tested for toxin production using cell culture assays. A total of 45 K. oxytoca isolates from IBD patients, healthy, asymptomatic carriers and from patients with antibiotic-associated hemorrhagic colitis in part from our strain collection were tested for their clonal relationship using MLST. RESULTS: The prevalence of K. oxytoca in IBD overall was 4.7%. Eleven K. oxytoca isolates were detected. Two of 11 isolates were tested positive for toxin production. There was no significant difference in the distribution of K. oxytoca isolates between the groups (active vs. remission in UC and CD). MLST yielded 33 sequence types. K. oxytoca isolates from IBD did not cluster separately from isolates from asymptomatic carriers. CONCLUSIONS: Our data demonstrate that toxin (tilivalline)-producing K. oxytoca is not associated with IBD flares.
Authors: Jane M M Natividad; Valerie Petit; Xianxi Huang; Giada de Palma; Jennifer Jury; Yolanda Sanz; Dana Philpott; Clara L Garcia Rodenas; Kathy D McCoy; Elena F Verdu Journal: Inflamm Bowel Dis Date: 2011-12-11 Impact factor: 5.325
Authors: Georg Schneditz; Jana Rentner; Sandro Roier; Jakob Pletz; Kathrin A T Herzog; Roland Bücker; Hanno Troeger; Stefan Schild; Hansjörg Weber; Rolf Breinbauer; Gregor Gorkiewicz; Christoph Högenauer; Ellen L Zechner Journal: Proc Natl Acad Sci U S A Date: 2014-08-25 Impact factor: 11.205
Authors: Ines Zollner-Schwetz; Christoph Högenauer; Martina Joainig; Paul Weberhofer; Gregor Gorkiewicz; Thomas Valentin; Thomas A Hinterleitner; Robert Krause Journal: Clin Infect Dis Date: 2008-11-01 Impact factor: 9.079
Authors: Shadi Sepehri; Ehsan Khafipour; Charles N Bernstein; Brian K Coombes; Ana V Pilar; Mohamed Karmali; Kim Ziebell; Denis O Krause Journal: Inflamm Bowel Dis Date: 2010-12-09 Impact factor: 5.325
Authors: Christoph Högenauer; Cord Langner; Eckhard Beubler; Irmgard T Lippe; Rudolf Schicho; Gregor Gorkiewicz; Robert Krause; Nikolas Gerstgrasser; Guenter J Krejs; Thomas A Hinterleitner Journal: N Engl J Med Date: 2006-12-07 Impact factor: 91.245
Authors: Martina M Joainig; Gregor Gorkiewicz; Eva Leitner; Paul Weberhofer; Ines Zollner-Schwetz; Irmgard Lippe; Gebhard Feierl; Robert Krause; Thomas Hinterleitner; Ellen L Zechner; Christoph Högenauer Journal: J Clin Microbiol Date: 2010-01-06 Impact factor: 5.948